Buscar en
Cirugía Española
Toda la web
Inicio Cirugía Española Estudio de las concentraciones del antígeno prostático específico en líquido...
Información de la revista
Vol. 69. Núm. 2.
Páginas 95-98 (Febrero 2001)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 69. Núm. 2.
Páginas 95-98 (Febrero 2001)
Acceso a texto completo
Estudio de las concentraciones del antígeno prostático específico en líquidos quísticos benignos mamarios. Correlación con otros parámetros clinicobiológicos
Study of prostate specific antigen levels in benign breast cyst fluids: correlation with other clinical and biological parameters
Visitas
4639
A. Ruibal*,**,1, M.J. Núñez***, V. Piqueras***, F. Rabadán***, M.C. del Río****, J. Schneider**,***, A. Tejerina**,***
* Servicio de Medicina Nuclear. Fundación Jiménez Díaz. Madrid.
** Fundación Tejerina. Madrid.
*** Centro de Patología de la Mama. Madrid.
**** Servicio de Bioquímica. Hospital de Barbanza. Ribeira.
Este artículo ha recibido
Información del artículo
Resumen
Introducción

El antígeno prostático específico (PSA, hK3) es una serín-proteasa no específica de la glándula prostática que puede ser detectada en los líquidos de quistes mamarios. El presente trabajo ha sido realizado con la finalidad de estudiar el comportamiento del PSA en líquidos de quistes mamarios benignos clasificados de acuerdo con la fase del ciclo menstrual, tipo de quiste y la existencia de quistes únicos o múltiples.

Pacientes y métodos

Hemos determinado, mediante un fluoroinmunoanálisis (Prostatus. PSA EQM. EC&G Wallac., Finlandia), las concentraciones de PSA en 160 líquidos de quistes mamarios benignos (134 tipo I, 26 tipo II, 42 únicos y 118 múltiples), correlacionándose con las de glucosa, pH, CEA y DHEA.

Resultados

Nuestros resultados fueron los siguientes: a) los quistes tipo I presentaron mayores concentraciones de PSA que los tipo II, no apreciándose diferencias cuando se consideraron la fase del ciclo menstrual y la existencia de quistes únicos o múltiples; b) en los quistes tipo I las concentraciones de PSA se correlacionaron significativamente con las de DHEA, mientras que en los quistes tipo II lo hicieron estadística y negativamente con las de glucosa, y c) en los quistes únicos no existieron diferencias en las concentraciones de PSA en función de la fase del ciclo menstrual, pero aquéllas fueron superiores estadísticamente en los quistes tipo I que en los tipo II; sin embargo, en los quistes múltiples no se constataron diferencias en las cifras de PSA cuando se consideraron el tipo y la fase del ciclo menstrual, las concentraciones de PSA fueron significativamente mayores en los quistes tipo II múltiples que en los tipos II únicos y no difirieron de las observadas en los quistes tipo I únicos.

Conclusiones

Nuestros resultados nos sugieren que el comportamiento del PSA en los líquidos de quistes mamarios benignos parece estar relacionado no sólo con el tipo I, sino también con la existencia de quistes múltiples.

Palabras clave:
PSA
Líquido quístico mamario
Introduction

Prostate specific antigen (PSA hK3) is a nonspecific serin protease produced by the prostate gland, and which may be detected in breast cyst fluids. The aim of the present study was to determine the behavior of PSA in benign breast cyst fluids classified by phase of the menstrual cycle, type of cyst, and the presence of single or multiple cysts.

Patients and methods

Using fluoroimmunoassay (Prostatus. PSA EQM. EC&G Wallac. Finland), PSA levels were calculated in 160 samples of benign breast cyst fluid (134 type I, 26 type II, 42 single and 118 multiple) and the findings were correlated with levels of glucose, pH, CEA and DHEA.

Results

Type I cysts presented higher PSA levels than type II cysts. There were no significant differences in PSA levels when phase of menstrual cycle and the presence of single or multiple cysts were taken into account. In type I cysts, there was a significant correlation between PSA levels and DHEA levels, while in type II cysts there was a negative statistical correlation between PSA levels and glucose. There were no differences in PSA levels in single cysts when menstrual phase was considered, but type I cysts had statistically higher PSA levels than type II cysts. There were no differences in PSA levels by menstrual phase or by type of cyst in multiple cysts. PSA levels were significantly higher in type II multiple cysts than in type II single cysts and did not differ from those observed in type I single cysts.

Conclusions

Our results suggest that the behavior of PSA levels in benign breast cyst fluid may be related not only to type I cysts but also to the existence of multiple cysts.

Key words:
PSA
Breast cyst fluids
El Texto completo está disponible en PDF
Bibliografía
[1.]
G.M. Yousef, L.Y. Luo, E.P. Diamandis.
Identification of novel human kallikrein-like genes on chromosome 19q13.3-q13.4.
Anticancer Res, 19 (1999), pp. 2843-2852
[2.]
J.E. Oesterling.
Prostate specific antigen: a valuable tool.
Oncology, 5 (1990), pp. 107-113
[3.]
J. Morate, A. Ruibal, J. Palou, J.A. De Torres, Roselló A. Soler.
Clinical evaluation of PSA and PAP. A comparative study..
Eur J Urology, 14 (1988), pp. 360-366
[4.]
E.P. Diamandis, G.M. Yousef, I. Luo, I. Magklara, C.V. Obiezu.
The new kallikrein gene family: implications in carcinogenesis.
Trends Endocrinol Metab, 11 (2000), pp. 54-60
[5.]
H Yu, H. Berkel.
Prostate specific antigen (PSA) in women..
J La State Med Soc, 151 (1999), pp. 209-213
[6.]
M.H. Black, E.P. Diamandis.
The diagnostic and prognostic utility of prostate specific antigen for diseases of the breast.
Breast Cancer Res Treat, 59 (2000), pp. 1-14
[7.]
S. Majumdar, E.P. Diamandis.
The promoter and the enhancer region of the KLK3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines.
Br J Cancer, 79 (1999), pp. 1594-1602
[8.]
L.C. Lai, H. Erbas, T.W. Lennard, R.T. Peaston.
Prostate specific antigen in breast cyst fluid: possible role of prostate specific antigen in hormone dependent breast cancer.
[9.]
H. Yu, M.A. Levesque, G.M. Clark, E.P. Diamandis.
Prognostic value of prostate specific antigen for women with breast cancer: a large United States cohort study..
Clin Cancer Res, 4 (1998), pp. 1489-1497
[10.]
E. Kucera, C. Kainz, C. Tempfer, R. Seillinger, H. Koelbl, G. Sliutz.
Prostate specific antigen (PSA) in breast and ovarian cancer.
Anticancer Res, 17 (1997), pp. 4735-4737
[11.]
J. Griniatsos, E. Diamantis, J. Gioti, I. Karyda, P.P. Vassilopoulos, N. Agnanti.
Correlation of prostate specific antigen immunoactivity (IE PSA) to other prognostic factors in female breast cancer.
Anticancer Res, 18 (1998), pp. 683-688
[12.]
E.R. Sauter, J. Babb, M. Daly, P.F. Engstrom, H. Ehta, J. Malick.
Prostate specific antigen production in the female breast: association with progesterone.
Cancer Epidemiol Biomarkers Prev, 7 (1998), pp. 315-320
[13.]
H. Yu, M.A. Levesque, G.M. Clark, E.P. Diamandis.
Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate specific antigen in combination.
Br J Cancer, 81 (1999), pp. 490-495
[14.]
J.A. Foekens, E.P. Diamandis, H. Yu, M.P. Look, M.E. Meijer Van Gelder, W.L. Van Putten.
Expression of prostate specific antigen (PSA) correlates with poor response to tamoxigen therapy in recurrent breast cancer.
Br J Cancer, 79 (1999), pp. 888-894
[15.]
E.R. Suater, M. Daly, K. Linahan, H. Ehya, P.F. Engstrom, G. Bonney.
Prostate specific antigen levels in nipple aspirate fluid correlate with breast cancer risk.
Cancer Epidemiol Biomarkers Prev, 5 (1996), pp. 967-970
[16.]
E.P. Diamandis, H. Yu, C. López Otin.
Protate specific antigen-a new constituent of breast cyst fluid.
Brest Cancer Res Treat, 38 (1996), pp. 259-264
[17.]
E.P. Diamandis.
Prostate specific antigen-new applications in breast and other cancers.
Anticancer Res, 16 (1996), pp. 3983-3984
[18.]
Mannello F, Bocchiotti G, Bianchi G, Marcheggiani F, Gazzanelli G. Quantification of prostate specific antigen immunoreactivity in human breast cyst fluids. Breast Cancer Res Treat 199; 38: 247-252.
[19.]
G.H. Borchert, H. Yu, G. Tomlinson, M. Giai, R. Roagna, R. Ponzone.
Prostate specific antigen molecular forms in breast cyst fluid and serum of women with fibrocystic breast disease.
J Clin Lab Anal, 13 (1999), pp. 75-81
[20.]
G.M. Yousef, E.P. Diamandis.
The expanded human kallikrein gene family: locus characterization and molecular cloning of a new member, KLK-L3.
Genomics, 65 (2000), pp. 184-194
[21.]
E.P. Diamandis, H. Yu.
Non prostatic sources of prostate specific antigen.
Urol Clin North Am, 24 (1997), pp. 275-282
[22.]
X. Filella, R. Molina, J. Alcover, V. Menéndez, N. Giménez, J. Jo.
Prostate specific antigen detection by ultrasensitive assay in samples from women.
[23.]
I. Abatte, M.D. Musci, F. Paradiso, F. Scituulli, M. Correale.
Determination of free PSA in breast cancer cytosols by IRMA.
Int J Biol Markers, 11 (1996), pp. 53-54
[24.]
A. Magklara, A. Scorilas, C. López Otin, F. Vizoso, A. Ruibal, E.P. Diamandis.
Human glandular kallikrein in breast milk, amniotic fluid, and breast cyst fluid.
Clin Chem, 45 (1999), pp. 1774-1780
[25.]
G.M. Yousef, C.V. Obiezu, L.Y. Luo, M.H. Black, E.P. Diamandis.
Prostate/KLK-L1 is a new, member of the human kallikrein gene family, is expressed in prostate and breast tissues, and is hormonally regulates.
Cancer Res, 59 (1999), pp. 4252-4256
[26.]
G.M. Yousef, A. Chang, E.P. Diamandis.
Identification and characterization of KLK-L4, a new kallilrein-like gene that appears to be downregulated in brast cancer tissues.
J Biol Chem, 275 (2000), pp. 11891-11898
[27.]
A. Magklara, L. Grass, E.P. Diamandis.
Differential steroid horome regulation of human glandular kallikrein (hK2) and prostate specific antigen (PSA) in breast cancer cell lines.
Breast Cancer Res Treat, 59 (2000), pp. 263-270
[28.]
M.H. Black, A. Magklara, C. Obiezu, M.A. Levesque, D.J. Sutherland, D.J. Tindall.
Expression of a prostate associated protein, human kallikrein (hk2) in breast tumours and in normal breast secretions.
Br J Cancer, 82 (2000), pp. 361-367
[29.]
G.H. Borchert, D.N. Melegos, H. Yu, M. Giai, R. Roagna, R. Ponzone.
Quantification of pepsinogen C and prostaglandin D synthase in breast cyst fluid and their potential utility for cyst type classification.
Clin Biochem, 32 (1999), pp. 39-44
[30.]
F. Manello, G. Bocchiotti, R. Troccolli, G. Gazzanelli.
Lipid assocaited sialic acid levels in human breast cyst fluids.
Breast Cancer Res Treat, 24 (1993), pp. 167-170
[31.]
J.M. Dixon, W.N. Scott, W.R. Miller.
Natural history of cystic disease: the importance of cyst type.
Br J Surg, 72 (1985), pp. 190-192
[32.]
D.E.Jr. Haagensen.
Is cystic disease related to breast cancer? Am J Surg Pathool, 15 (1991), pp. 687-694
[33.]
M. Malatesta, F. Mannrello, M. Asebastini, G. Bianchi, G. Gazzanelli.
Prostate specific antigen found in type I breast cyst fluids is a secretory product of the apocrine cells lining breast gross cysts.
Breast Cancer Res Treat, 57 (1999),
Copyright © 2001. Asociación Española de Cirujanos
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos